PubRank

William C Hahn

Author PubWeight™ 435.97‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006 18.81
2 Initial genome sequencing and analysis of multiple myeloma. Nature 2011 17.28
3 Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007 17.20
4 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 14.62
5 BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011 14.34
6 Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006 11.90
7 Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009 11.46
8 Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011 8.37
9 Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003 8.07
10 Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007 7.60
11 SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009 7.48
12 Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 2008 7.45
13 A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004 6.61
14 Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009 6.55
15 CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008 6.24
16 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005 6.04
17 Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006 5.96
18 Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009 5.63
19 High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2011 5.30
20 A public genome-scale lentiviral expression library of human ORFs. Nat Methods 2011 4.98
21 Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 4.96
22 Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 2008 4.71
23 AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009 4.71
24 Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006 4.68
25 Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006 4.52
26 Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008 4.46
27 The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest 2011 4.41
28 The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008 4.32
29 Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011 4.15
30 Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 2006 4.12
31 Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002 4.04
32 Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002 3.80
33 Chemosensitivity linked to p73 function. Cancer Cell 2003 3.63
34 Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012 3.44
35 Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003 3.33
36 β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012 3.33
37 Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004 3.29
38 Telomerase maintains telomere structure in normal human cells. Cell 2003 3.29
39 Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003 3.23
40 Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013 3.19
41 An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010 3.09
42 Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 2012 3.06
43 An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009 3.04
44 A genetically defined model for human ovarian cancer. Cancer Res 2004 3.02
45 Making sense of cancer genomic data. Genes Dev 2011 3.01
46 An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010 2.85
47 Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002 2.82
48 Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol 2011 2.69
49 PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010 2.68
50 A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002 2.66
51 Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012 2.63
52 Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009 2.53
53 Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008 2.52
54 A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008 2.48
55 The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 2013 2.46
56 Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009 2.39
57 Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004 2.32
58 Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell 2006 2.15
59 Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009 2.15
60 Roots and stems: stem cells in cancer. Nat Med 2006 2.13
61 The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 2007 2.10
62 Involvement of PP2A in viral and cellular transformation. Oncogene 2005 2.07
63 The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005 2.01
64 Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009 2.00
65 Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 2010 1.98
66 Cancer vulnerabilities unveiled by genomic loss. Cell 2012 1.95
67 An oncogenic role for ETV1 in melanoma. Cancer Res 2010 1.94
68 Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A 2008 1.92
69 Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A 2010 1.91
70 ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 2012 1.86
71 Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol 2005 1.81
72 Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 2003 1.78
73 The current state of preclinical prostate cancer animal models. Prostate 2008 1.68
74 Towards patient-based cancer therapeutics. Nat Biotechnol 2010 1.63
75 Oncogenic transformation and experimental models of human cancer. Front Biosci 2008 1.59
76 HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell 2013 1.58
77 Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011 1.57
78 Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013 1.52
79 Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 2005 1.52
80 Evolving views of telomerase and cancer. Trends Cell Biol 2003 1.47
81 Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010 1.47
82 Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004 1.46
83 Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 2012 1.42
84 Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004 1.42
85 Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010 1.40
86 CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol 2010 1.35
87 SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal 2009 1.35
88 SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 2008 1.34
89 The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005 1.34
90 Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A 2012 1.34
91 Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013 1.33
92 Structural basis of PP2A inhibition by small t antigen. PLoS Biol 2007 1.32
93 Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol 2003 1.32
94 Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 2010 1.29
95 BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 2008 1.28
96 Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 2014 1.28
97 High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 2011 1.28
98 PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 2009 1.27
99 Towards systematic functional characterization of cancer genomes. Nat Rev Genet 2011 1.27
100 Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014 1.26
101 The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J Clin Invest 2012 1.24
102 CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One 2010 1.22
103 Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 2013 1.22
104 Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013 1.17
105 Functional genetics and experimental models of human cancer. Trends Mol Med 2004 1.17
106 RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest 2013 1.16
107 PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 2010 1.15
108 MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal 2012 1.13
109 PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006 1.13
110 MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009 1.12
111 CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer 2010 1.11
112 Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood 2012 1.11
113 Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res 2013 1.10
114 Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011 1.09
115 Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 2013 1.09
116 Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res 2009 1.09
117 Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov 2011 1.07
118 Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006 1.07
119 Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A 2005 1.05
120 Functional genomics and cancer drug target discovery. Curr Opin Mol Ther 2010 1.05
121 The perfect storm: challenges and opportunities for translational medicine. J Clin Invest 2013 1.05
122 Unexpected pieces to the senescence puzzle. Cell 2008 1.04
123 Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol 2005 1.03
124 Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev 2013 1.00
125 Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014 1.00
126 Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007 0.99
127 Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005 0.99
128 In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A 2014 0.99
129 Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown. Cancer Res 2004 0.98
130 Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest 2012 0.98
131 Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration. Fitoterapia 2010 0.97
132 Nucleolin interacts with telomerase. J Biol Chem 2004 0.93
133 Understanding transformation: progress and gaps. Curr Opin Genet Dev 2005 0.93
134 IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Mol Cell Biol 2012 0.92
135 RMRP is a non-coding RNA essential for early murine development. PLoS One 2011 0.91
136 Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res 2014 0.90
137 The role of PP2A A subunits in tumor suppression. Cell Adh Migr 2007 0.89
138 Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One 2013 0.88
139 Telomerase and tumorigenesis. Cancer Lett 2003 0.88
140 IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep 2013 0.87
141 Therapeutic implications of GIPC1 silencing in cancer. PLoS One 2010 0.87
142 Cancer genomics: integrating form and function. Carcinogenesis 2007 0.87
143 Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol 2012 0.84
144 Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 2014 0.83
145 Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts. Mol Cell Biol 2012 0.83
146 High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Invest Ophthalmol Vis Sci 2012 0.82
147 Bladder cancer: modeling and translation. Genes Dev 2009 0.82
148 Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Lett 2005 0.82
149 Liprin alpha1 interacts with PP2A B56gamma. Cell Cycle 2007 0.82
150 Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther 2011 0.81
151 In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004 0.81
152 Immortalized cells as experimental models to study cancer. Cytotechnology 2004 0.79
153 Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol (Camb) 2014 0.79
154 Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data. Bioinformatics 2007 0.78
155 Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol Cancer Res 2008 0.76
156 Cancer genetics: Finding the right mix. Eur J Hum Genet 2005 0.75
157 EGFR in limbo. Cell 2012 0.75
158 On or off target: mutations, models, and predictions. Sci Transl Med 2010 0.75
159 AACR Cancer Progress Report 2015. Clin Cancer Res 2015 0.75
160 Telomerase expression--only half the story. Cancer Biol Ther 2003 0.75
161 Regulating TERT: location, location, location. Cell Cycle 2009 0.75
162 The role of specific PP2A complexes in the dephosphorylation of γH2AX. J Cell Sci 2014 0.75
163 Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife 2017 0.75
164 Genetic alterations in prostate cancer. Clin Prostate Cancer 2005 0.75
165 New Functions for Telomerase. Cancer Res Treat 2003 0.75
166 Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun 2017 0.75
167 The origin of cancer. Cancer Treat Res 2004 0.75
168 Prospects for anti-neoplastic therapies based on telomere biology. Curr Cancer Drug Targets 2002 0.75
169 Genetic and cellular mechanisms of oncogenesis. Curr Opin Genet Dev 2009 0.75